Literature DB >> 21055630

Synthesis and in vivo brain distribution of carbon-11-labeled δ-opioid receptor agonists.

Rama Pichika1, Douglas M Jewett, Philip S Sherman, John R Traynor, Stephen M Husbands, James H Woods, Michael R Kilbourn.   

Abstract

Three new radiolabeled compounds, [(11)C]SNC80 ((+)-4-[(αR)-α-{(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl}-3-[(11)C]methoxybenzyl-N,N-diethylbenzamide), N,N-diethyl-4-[3-methoxyphenyl-1-[(11)C]methylpiperidin-4-ylidenemethyl)benzamide and N,N-diethyl-4-[(1-[(11)C]methylpiperidin-4-ylidene)phenylmethyl]benzamide, were prepared as potential in vivo radiotracers for the δ-opioid receptor. Each compound was synthesized by alkylation of the appropriate desmethyl compounds using [(11)C]methyl triflate. In vivo biodistribution studies in mice showed very low initial brain uptake of all three compounds and no regional specific binding for [(11)C]SNC80. A monkey positron emission tomography study of [(11)C]SNC80 confirmed low brain permeability and uniform regional distribution of this class of opioid agonists in a higher species. Opioid receptor ligands of this structural class are thus unlikely to succeed as in vivo radiotracers, likely due to efficient exclusion from the brain by the P-glycoprotein efflux transporter.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21055630      PMCID: PMC3018154          DOI: 10.1016/j.nucmedbio.2010.06.002

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  26 in total

Review 1.  PET imaging of the opioid receptor: the early years.

Authors:  J J Frost
Journal:  Nucl Med Biol       Date:  2001-07       Impact factor: 2.408

Review 2.  PET: opiate neuroreceptor mapping.

Authors:  M J Koepp; J S Duncan
Journal:  Adv Neurol       Date:  2000

3.  N,N-Diethyl-4-(phenylpiperidin-4-ylidenemethyl)benzamide: a novel, exceptionally selective, potent delta opioid receptor agonist with oral bioavailability and its analogues.

Authors:  Z Y Wei; W Brown; B Takasaki; N Plobeck; D Delorme; F Zhou; H Yang; P Jones; L Gawell; H Gagnon; R Schmidt; S Y Yue; C Walpole; K Payza; S St-Onge; M Labarre; C Godbout; A Jakob; J Butterworth; A Kamassah; P E Morin; D Projean; J Ducharme; E Roberts
Journal:  J Med Chem       Date:  2000-10-19       Impact factor: 7.446

4.  Interaction of nonpeptidic delta agonists with P-glycoprotein by in situ mouse brain perfusion: liquid chromatography-mass spectrometry analysis and internal standard strategy.

Authors:  Claude Dagenais; Julie Ducharme; Gary M Pollack
Journal:  J Pharm Sci       Date:  2002-01       Impact factor: 3.534

5.  Immunosuppression by delta-opioid antagonist naltrindole: delta- and triple mu/delta/kappa-opioid receptor knockout mice reveal a nonopioid activity.

Authors:  C Gavériaux-Ruff; D Filliol; F Simonin; H W Matthes; B L Kieffer
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

6.  In vivo binding of N1'-([11C]methyl)naltrindole to delta-opioid receptors in mouse brain.

Authors:  J R Lever; U Scheffel; C M Kinter; H T Ravert; R F Dannals; H N Wagner; J J Frost
Journal:  Eur J Pharmacol       Date:  1992-06-17       Impact factor: 4.432

7.  A simple synthesis of [11C]methyl triflate.

Authors:  D M Jewett
Journal:  Int J Rad Appl Instrum A       Date:  1992-11

8.  Behavioral effects of the systemically active delta opioid agonist BW373U86 in rhesus monkeys.

Authors:  S S Negus; E R Butelman; K J Chang; B DeCosta; G Winger; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1994-09       Impact factor: 4.030

9.  Synthesis of (2-[11C]methoxy)rotenone, a marker of mitochondrial complex I activity.

Authors:  A Charalambous; T J Mangner; M R Kilbourn
Journal:  Nucl Med Biol       Date:  1995-01       Impact factor: 2.408

10.  The delta-opioid receptor antagonist naltrindole prevents sensitization to the conditioned rewarding effects of cocaine.

Authors:  T S Shippenberg; C Heidbreder
Journal:  Eur J Pharmacol       Date:  1995-06-23       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.